T
TFF Pharmaceuticals
Biotech & Life Sciences · Austin, United States · Founded 2018 · IPO 2019
Early-stage biopharmaceutical company MoreLess
TFF Pharmaceuticals specializes in developing advanced inhalation therapies using its proprietary Thin Film Freezing (TFF) technology. The company focuses on creating dry powder formulations for direct-to-lung delivery, which can improve the efficacy and safety of various medications. TFF Pharmaceuticals serves the pharmaceutical and biotechnology sectors, targeting conditions such as lung transplant rejection and fungal infections. The business model involves research and development, clinical trials, and partnerships with other pharmaceutical companies to bring its products to market. Revenue is generated through licensing agreements, milestone payments, and eventual product sales.
Keywords: Thin Film Freezing, inhalation therapies, dry powder, lung delivery, pharmaceutical, biotechnology, drug formulation, clinical trials, lung transplant, fungal infections.
Talent graph
TFF Pharmaceuticals's talent
Source: Dealroom Talent Intelligence.
Investors
2 investors on TFF Pharmaceuticals's cap table
Sourced from Dealroom's funding and investor records.


Global footprint
Where TFF Pharmaceuticals has talent and traffic
Market sentiment
What the market is saying about TFF Pharmaceuticals
An AI-synthesized read of the highest-engagement posts about TFF Pharmaceuticals on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See TFF Pharmaceuticals on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.